While the frequency of pathogenic variants in BRCA1 and BRCA2 is high in the Ashkenazi Jewish population [60, 61], it was found that 0.3% of all Ashkenazi Jewish breast cancer patients were double heterozygotes for BRCA1/2 pathogenic variants [62]. This evidence concerns the gene BRCA1 and breast carcinoma.